羟钴胺(Hydroxocobalamin) - 药物靶点：IFNAR_在研适应症：氰化物中毒，弱视，Leber氏遗传性视神经萎缩_专利_临床

概要

基本信息

药物类型

化学药

别名

HXC、Hydroxocobalamin (JAN/USP/INN)、Hydroxocobalamin anhydrous

+ [14]

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)

治疗领域

神经系统疾病遗传病与畸形内分泌与代谢疾病+ [3]

在研适应症

氰化物中毒弱视Leber氏遗传性视神经萎缩+ [6]

非在研适应症-

原研机构

在研机构

+ [5]

非在研机构

Merck & Co., Inc.

最高研发阶段批准上市

首次获批日期

美国 (1975-04-18),

中毒

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C62H89CoN13O15P

InChIKeyXVXCLEXSDVMESA-UHFFFAOYSA-L

CAS号13422-51-0

关联

16

项与羟钴胺相关的临床试验

NCT04259060

/ Withdrawn临床2期IIT

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative

This is a 4-week pilot, multicenter, randomized, double-blinded placebo controlled trial of hydroxocobalamin and butyrate in ulcerative colitis (UC) that will occur in two phases. The main objectives of this study are to determine the capacity of hydroxocobalamin and butyrate to reduce calprotectin in those with inflammatory disease in UC to determine the safety and preferential dose of hydroxocobalamin with butyrate in UC.

开始日期2024-01-01

申办/合作机构

The Brigham & Women's Hospital, Inc.

NCT05536596

/ Not yet recruiting临床2/3期IIT

Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy: a Randomized, Double-blind Trial

The bilateral sagittal split osteotomy (BSSO) of the mandible is one of the most used surgical techniques to achieve a harmonious jaw relation in the context of orthognathic surgery. Nevertheless, one of its main complications is neurosensory damage to the inferior alveolar nerve, which can cause severe impact in the quality of life on patients who suffer from it permanently. The purpose of this randomized clinical trial is to provide rigorous scientific evidence of the pharmacological effect of 1) Melatonin, 2) combination uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxycobalamin (UTP/CMP/hydroxycobalamin) and 3) hydroxycobalamin regarding neurosensory disturbances incidence and persistence after BSSO.

开始日期2022-09-30

申办/合作机构

Universitat Internacional de Catalunya

[+1]

IRCT20211207053311N1

/ Recruiting临床3期IIT

Evaluation of response rate to hydroxycobalamin treatment in patients with methylmalonic acidemia

开始日期2022-02-04

申办/合作机构

Mashhad University of Medical Sciences

100 项与羟钴胺相关的临床结果

登录后查看更多信息

100 项与羟钴胺相关的转化医学

登录后查看更多信息

100 项与羟钴胺相关的专利（医药）

登录后查看更多信息

3,742

项与羟钴胺相关的文献（医药）

2025-02-01·Archivos Argentinos de Pediatria

Acute cyanide intoxication due to apricot seed ingestion

Article

作者: Güngör, Emre ; Orhan, Özhan ; Talay, Mehmet N

Introduction: Cyanide poisoning, whether it be accidental or intentional, remains a significant danger to adults and children, especially in societies where agriculture is a primary source of income. We examined the clinical follow-up, complications, and results of cyanide poisoning cases that occurred after eating the pits and seeds of plants containing cyanide glycosides, such as apricot kernels and almonds. Methods: Between 01/01/2017 and 01/08/2022, 14 children aged 1-18 years who were followed up with a prediagnosis of cyanide poisoning in our Paediatric Intensive Care Unit (PICU) were retrospectively analysed. Results: Eight of the patients followed with a preliminary diagnosis of cyanide poisoning were female and six were male. The most common admission month was July (42.8%) coinciding with the agricultural season. The most common symptoms at presentation were weakness and fatigue (n = 7). In the PICU, 4 patients presented lip cyanosis; 3, altered level of consciousness. Vomiting, seizure, headache, dizziness and palpitatons were less frequent. Four patients were treated with hydroxocobalamin (Cyanokit®) as an antidote due to acidosis in their blood gases. All patients treated for cyanide poisoning were discharged. Conclusions: Cyanide poisoning should be considered in paediatric patients with suspicious findings, sudden loss of consciousness, increased anion gap acidosis and lactic acidosis. The history of eating the seeds of plants such as apricot and almonds should be investigated.

2025-02-01·Bioresource Technology

Membrane photobioreactor for biogas capture and conversion – Enhanced microbial interaction in biofilm

Article

作者: Zhang, Baorui ; Zhou, Yan ; Cai, Chen ; Liu, Jianbo

The urgency to mitigate greenhouse gas emissions has driven interest in sustainable biogas utilization. This study investigates a 1 L enclosed membrane photobioreactor (MPBR) using a microalgae-methanotroph coculture for biogas capture. Operating with a hydraulic and solid retention time of 7 days and a biogas loading rate of 2.7 L /day, the introduction of gas membrane module increased CO₂-C and CH₄-C uptake rates by 12 % and 50 %, respectively. Biofilm formation on the membrane surface enhanced system performance, with imaging analyses revealing methanotroph predominantly located near the membrane surface and photosynthetic microorganisms distributed throughout. Metagenomic analysis showed shifts in key metabolic pathways, including increased abundance of soluble methane monooxygenase genes and enhanced vitamin B synthesis in the biofilm. These findings highlight the spatial organization and metabolic interactions in methanotroph-microalgae coculture system, providing insights into the role of membrane-induced biofilms in improving MPBR performance for sustainable biogas utilization.

2025-01-01·Food Chemistry

Impact of fermentation by Saccharomyces Cerevisiae on the macronutrient and in vitro digestion characteristics of Chinese noodles

Article

作者: Sun, Jingwei ; Liu, Shuhang ; Yao, Ke ; Qiu, Shoukuan ; Song, Xiaoyan

This study examined the impact of live bread yeast (Saccharomyces cerevisiae) on the nutritional characteristics of Asian dried noodles. Micronutrient analysis of fermented noodles revealed a 6.9% increase in the overall amino acid content, a 37.1% increase in the vitamin B content and a 63.0% decrease in the phytic acid level. Molecular weight analysis of starch and protein contents revealed moderate decrease in the fermented noodles. The in vitro digestion of fermented noodles showed a slightly faster initial acidification, four-fold decrease in the initial shear viscosity (from 8.85 to 1.94 Pa·s). The initial large food particle count (>2 mm diameter) was 19.5% lower in the fermented noodles. The fermented noodles contained slightly higher free sugar content (73.5 mg g^-1 noodle) during the gastric digestion phase. The overall nutrition and digestion results indicate nutritional improvement and digestion-easing attributes in the fermented noodles.

2

项与羟钴胺相关的新闻（医药）

2025-01-14

·石药集团

华荣制药成为国内首个获得盐酸羟钴胺欧盟CEP注册证书的生产企业

近日，喜讯传来！石药集团下属公司河北华荣制药有限公司（下称：“华荣制药”）生产的盐酸羟钴胺成功获得了欧洲药品质量管理局（EDQM）颁发的CEP证书（证书号NO.CEP 2023-256-Rev 00），成为国内首家获得该证书的盐酸羟钴胺生产企业。这一重要里程碑标志着华荣制药在国际化道路上迈出了坚实的一步，同时也提升了石药集团在全球医药市场的竞争力。河北华荣制药有限公司自1993年建厂至今，已成为全球重要的维生素B12全系列产品生产商和供应商，维生素B12系列产品共有7个医药级品种，10余个食品级、饲料级品种，包含维生素B12（氰钴胺）、甲钴胺、腺苷钴胺、羟钴胺和维生素B12饲料添加剂等，能够生产全系列维生素B12的产品。同时，有着30年维生素B12生产历史的华荣制药，多次参与了多品种的药典、国标修订升版工作，向国家药典委员会提供工作标准品、样品、检测分析方法，引领行业技术标准。此次获得CEP证书的产品：盐酸羟钴胺，作为一种重要的维生素B12类药物，在临床治疗中有着广泛应用，主要用于治疗恶性贫血、巨幼红细胞性贫血、神经痛、肝实质损害与接触性皮炎等，特别在氰化物中毒解救中发挥着重要作用。在申报过程中，华荣制药积极与EDQM进行沟通交流，就官方提出的发补项，快速响应，查阅学习法规指南，开展相关实验，充分展示了公司注册和技术人员能担当、敢挑战、使命必达的工作精神，最终华荣制药较原申报计划提前六个月成功获得此次CEP证书。 CEP证书是欧洲药品市场准入的重要凭证，可以证明华荣制药的盐酸羟钴胺产品完全符合欧洲药典标准，不仅是对华荣制药产品质量和研发实力的高度认可，也将进一步推动公司国际化战略的深入实施。下一步，华荣制药将不断提升产品质量，拓展更多产品的国际市场准入，一如既往坚守“做好药，为中国，善报天下人”的使命，努力成为具有国际竞争力的制药企业。【声明】1、本新闻旨在分享信息，非广告用途； 2、本资料仅供医药专业人士参考，非产品推荐依据，也不应被视为诊疗建议。

申请上市

2024-11-23

·米内网

【瞩目】狙击超1700亿市场，华润发力儿科罕见病药

精彩内容近日，CDE发布通知，华润双鹤药业的羟钴胺注射液纳入以患者为中心的罕见疾病药物研发试点工作（“关爱计划”），拟用于儿童甲基丙二酸血症（MMA）伴或不伴同型半胱氨酸血症患者代谢紊乱的治疗。2023年中国三大终端六大市场血液和造血系统药物销售额超1700亿元。来源：CDE官网羟钴胺是维生素B12的的同类物，参与人体内甲基转换及叶酸代谢，促进5-甲基四氢叶酸转变为四氢叶酸。其药用产品为盐酸羟钴胺注射液，用于治疗恶性贫血、巨幼红细胞性贫血、神经痛、肝实质损害与接触性皮炎，也用于治疗氰化物中毒等。盐酸羟钴胺注射液属于血液和造血系统药物，米内网数据显示，近年来该品类（化药+生物药）在中国三大终端六大市场（统计范围详见本文末）销售规模逐年扩容，2023年拿下超1700亿元，同比增长7.52%，2024上半年收获约870亿元。目前该药仅上海锦帝九州药业拥有生产批文。中国三大终端六大市场血液和造血系统药物（化药+生物药）销售趋势（单位：万元）来源：米内网格局数据库近年来，华润双鹤药业持续加大药品研发创新力度，2022年研发费用4.82亿元，同比增长17.80%；2023年研发费用5.61亿元，同比增长16.37%；2024年前三季度研发费用4.73亿元，同比增长14.33%。在研新药方面，公司已布局十余个创新药项目，其中5.1类新药八氟丙烷脂质微球注射液（肝脏超声微泡造影剂）、2.2类新药巯嘌呤微片（治疗儿童白血病）已提交上市申请在审，生物类似药司美格鲁肽注射液（治疗2型糖尿病）处于Ⅲ期临床研究阶段，1类新药DC05F01（治疗卵巢癌等晚期实体瘤）处于Ⅰb/Ⅱa期临床研究阶段，改良型新药ZP036（用于由黄体酮缺乏引起的机能障碍）已获批临床。华润双鹤药业主要在研新药来源：米内网中国申报进度（MED）数据库日前，华润双鹤药业发布2024年三季度报，报告期内，公司实现营业收入85.48亿元，归母净利润13.97亿元,；扣非净利润12.57亿元，同比增长23.91%；业绩呈稳步上升的态势。来源：米内网数据库、CDE官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至11月22日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

临床3期生物类似药财报

100 项与羟钴胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01027	羟钴胺	V03AB33 B03BA03	DB00200

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
氰化物中毒	美国	BTG International, Inc.	2006-12-15
弱视	澳大利亚	Pfizer Australia Pty Ltd.	2006-06-26
Leber氏遗传性视神经萎缩	澳大利亚	Pfizer Australia Pty Ltd.	2006-06-26
巨幼红细胞性贫血	中国	上海锦帝九州药业（安阳）有限公司	1996-01-01
巨幼红细胞性贫血	中国	华润双鹤药业股份有限公司	1996-01-01
恶性贫血	中国	上海锦帝九州药业（安阳）有限公司	1996-01-01
恶性贫血	中国	华润双鹤药业股份有限公司	1996-01-01
神经痛	中国	上海锦帝九州药业（安阳）有限公司	1996-01-01
神经痛	中国	华润双鹤药业股份有限公司	1996-01-01
维生素B12缺乏症	中国	上海锦帝九州药业（安阳）有限公司	1996-01-01
维生素B12缺乏症	中国	华润双鹤药业股份有限公司	1996-01-01
中毒	美国	Actavis	1978-08-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲基丙二酸血症	临床前	美国	National Institutes of Health	2024-10-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04054999 (CTgov)	临床4期	血管麻痹 \| 肝移植排斥反应	19	Hydroxocobalamin (Cyanokit)	窪餘窪觸簾窪膚糧網選(壓繭鬱選築艱鹽範製艱) = 獵觸鏇遞廠簾襯選餘鏇壓糧築願蓋鏇願築淵窪 (範醖窪糧鹹鹹襯廠遞蓋, 遞築築簾壓衊築齋願鬱 ~ 築積鹽艱鬱壓簾積衊鏇) 更多	-	2024-06-24
				Methylene Blue (Methylene Blue)	窪餘窪觸簾窪膚糧網選(壓繭鬱選築艱鹽範製艱) = 壓壓構膚糧憲構簾窪顧壓糧築願蓋鏇願築淵窪 (範醖窪糧鹹鹹襯廠遞蓋, 憲願範製選鏇夢願衊範 ~ 觸鹹積範鏇壓蓋夢餘遞) 更多
ATS2023	N/A	-	-	Hydroxycobalamin	(窪願醖醖鬱醖積淵憲淵) = 遞繭網築鹽蓋繭獵獵鬱淵衊襯積衊壓鹹範顧艱 (遞鏇網選憲積蓋鏇構願 ) 更多	-	2023-05-21
				Vasopressors (norepinephrine, vasopressin, epinephrine)	(窪願醖醖鬱醖積淵憲淵) = 窪觸簾製鹽構選膚夢鏇淵衊襯積衊壓鹹範顧艱 (遞鏇網選憲積蓋鏇構願 ) 更多
NCT03735316 (CTgov)	临床2期	血管麻痹 \| 低血压	8	Cardiopulmonary Bypass+Hydroxocobalamin (B12a)	鹽鬱齋築簾憲鹽膚遞淵(網壓觸積齋壓壓齋壓網) = 膚積鹽窪積願蓋製廠觸遞範觸構積淵齋鹽醖憲 (構繭鑰淵窪築範淵膚鏇, 鹽構鹹淵願衊選構製鑰 ~ 積窪壓範鏇簾夢築餘繭) 更多	-	2023-05-10
				Cardiopulmonary Bypass (Placebo)	鹽鬱齋築簾憲鹽膚遞淵(網壓觸積齋壓壓齋壓網) = 鑰醖衊繭築觸襯鹽獵艱遞範觸構積淵齋鹽醖憲 (構繭鑰淵窪築範淵膚鏇, 醖築鏇鹽膚築觸鏇獵窪 ~ 醖鑰蓋繭膚醖願選積膚) 更多
SSIEM2022	N/A	Transcobalamin II缺乏症 vitamin B12 \| folic acid \| homocysteine ... 更多	-	Parenteral hydroxocobalamin	積憲夢積夢觸鏇廠餘壓(衊糧繭遞網衊範襯網餘) = 憲製顧鑰艱醖齋範壓選積繭簾製製壓窪繭齋糧 (膚獵廠鹽壓繭糧網蓋夢 ) 更多	-	2022-08-30
ATS2021	N/A	血管麻痹	-	Hydroxocobalamin	(餘遞廠窪獵顧窪鹽壓鹹) = 積願衊醖鹹遞構憲餘壓壓築鏇遞憲簾鹽鏇積鏇 (夢齋範積願廠襯淵築廠 )	-	2021-05-03
START Program (ASH2007)	N/A	急性转化期慢性粒细胞性白血病	157	Dasatinib 70 mg BID	範襯繭簾糧選鏇膚醖鑰(醖淵積夢餘鏇鬱襯襯艱) = Cytopenias were noted for the majority of patients, and were manageable; grade 3-4 febrile neutropenia was recorded in 8% of patients 繭網鑰壓構糧鏇遞觸鬱 (鬱艱製膚網蓋膚壓窪醖 ) 更多	-	2007-11-16
				Cbi